Orexo AB (publ) (ORXOY)
ORXOY Stock Price Chart
Explore Orexo AB (publ) interactive price chart. Choose custom timeframes to analyze ORXOY price movements and trends.
ORXOY Company Profile
Discover essential business fundamentals and corporate details for Orexo AB (publ) (ORXOY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Mar 2018
Employees
110.00
Website
https://www.orexo.comCEO
Nikolaj Sorensen
Description
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
ORXOY Financial Timeline
Browse a chronological timeline of Orexo AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 5 Feb 2026
Upcoming earnings on 23 Oct 2025
Earnings released on 16 Jul 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $14.01M , missing expectations by -89.66%.
Earnings released on 5 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.12 by +61.33%, while revenue for the quarter reached $14.60M , missing expectations by -89.78%.
Earnings released on 6 Feb 2025
EPS came in at -$0.30 falling short of the estimated -$0.15 by -106.12%, while revenue for the quarter reached $14.43M , missing expectations by -90.25%.
Earnings released on 24 Oct 2024
EPS came in at -$0.12 falling short of the estimated -$0.07 by -59.24%, while revenue for the quarter reached $13.16M , missing expectations by -9.35%.
Earnings released on 17 Jul 2024
EPS came in at -$0.10 falling short of the estimated -$0.04 by -162.09%, while revenue for the quarter reached $14.57M , missing expectations by -2.35%.
Earnings released on 8 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.07 by +66.88%, while revenue for the quarter reached $12.84M , missing expectations by -4.77%.
Earnings released on 5 Mar 2024
EPS came in at -$0.05 falling short of the estimated -$0.05 by -15.13%, while revenue for the quarter reached $16.42M , beating expectations by +10.61%.
Earnings released on 30 Sept 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -4.67%, while revenue for the quarter reached $14.17M , beating expectations by +0.70%.
Earnings released on 30 Jun 2023
EPS came in at -$0.03 , while revenue for the quarter reached $14.53M .
Earnings released on 31 Mar 2023
EPS came in at -$0.18 falling short of the estimated -$0.08 by -110.36%, while revenue for the quarter reached $15.26M , beating expectations by +7.48%.
Earnings released on 31 Dec 2022
EPS came in at -$0.26 , while revenue for the quarter reached $15.23M .
Earnings released on 30 Sept 2022
EPS came in at -$0.07 , while revenue for the quarter reached $14.37M .
Earnings released on 30 Jun 2022
EPS came in at -$0.10 , while revenue for the quarter reached $14.37M .
Earnings released on 31 Mar 2022
EPS came in at -$0.07 , while revenue for the quarter reached $16.99M .
Earnings released on 31 Dec 2021
EPS came in at -$0.18 , while revenue for the quarter reached $15.87M .
Earnings released on 30 Sept 2021
EPS came in at -$0.17 , while revenue for the quarter reached $16.62M .
Earnings released on 30 Jun 2021
EPS came in at -$0.25 , while revenue for the quarter reached $16.64M .
Earnings released on 31 Mar 2021
EPS came in at -$0.11 , while revenue for the quarter reached $15.13M .
Earnings released on 31 Dec 2020
EPS came in at -$0.17 , while revenue for the quarter reached $19.32M .
Earnings released on 30 Sept 2020
EPS came in at -$0.27 , while revenue for the quarter reached $16.79M .
ORXOY Stock Performance
Access detailed ORXOY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.